Carrera Capital Advisors Buys Shares of 24,687 Johnson & Johnson $JNJ

Carrera Capital Advisors purchased a new position in Johnson & Johnson (NYSE:JNJ) in the third quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm purchased 24,687 shares of the company’s stock, valued at approximately $4,577,000. Johnson & Johnson accounts for approximately 0.8% of Carrera Capital Advisors’ portfolio, making the stock its 24th largest position.

A number of other hedge funds and other institutional investors also recently made changes to their positions in the stock. Evolution Wealth Management Inc. bought a new position in Johnson & Johnson in the 2nd quarter valued at $27,000. Clayton Financial Group LLC purchased a new stake in Johnson & Johnson in the third quarter valued at approximately $28,000. Semmax Financial Advisors Inc. lifted its position in Johnson & Johnson by 55.0% during the second quarter. Semmax Financial Advisors Inc. now owns 203 shares of the company’s stock valued at $31,000 after purchasing an additional 72 shares during the last quarter. GFG Capital LLC purchased a new position in Johnson & Johnson in the 2nd quarter worth approximately $35,000. Finally, Signature Resources Capital Management LLC increased its holdings in shares of Johnson & Johnson by 262.9% in the 3rd quarter. Signature Resources Capital Management LLC now owns 254 shares of the company’s stock worth $47,000 after buying an additional 184 shares during the last quarter. 69.55% of the stock is currently owned by institutional investors.

Johnson & Johnson Trading Up 1.6%

NYSE JNJ opened at $230.82 on Tuesday. The firm has a market cap of $556.11 billion, a PE ratio of 20.89, a price-to-earnings-growth ratio of 2.21 and a beta of 0.35. Johnson & Johnson has a 1-year low of $141.50 and a 1-year high of $231.19. The stock has a 50-day moving average of $211.21 and a 200-day moving average of $192.24. The company has a current ratio of 1.07, a quick ratio of 0.80 and a debt-to-equity ratio of 0.50.

Johnson & Johnson (NYSE:JNJ) last announced its quarterly earnings results on Wednesday, January 21st. The company reported $2.46 EPS for the quarter, hitting analysts’ consensus estimates of $2.46. Johnson & Johnson had a return on equity of 33.34% and a net margin of 28.46%.The business had revenue of $24.56 billion for the quarter, compared to analysts’ expectations of $24.14 billion. During the same period in the previous year, the firm earned $2.04 EPS. The business’s quarterly revenue was up 9.1% on a year-over-year basis. Johnson & Johnson has set its FY 2026 guidance at 11.430-11.630 EPS. As a group, sell-side analysts forecast that Johnson & Johnson will post 10.58 EPS for the current year.

Johnson & Johnson Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Tuesday, March 10th. Shareholders of record on Tuesday, February 24th will be issued a $1.30 dividend. This represents a $5.20 dividend on an annualized basis and a yield of 2.3%. The ex-dividend date of this dividend is Tuesday, February 24th. Johnson & Johnson’s dividend payout ratio (DPR) is 47.06%.

Analyst Ratings Changes

A number of analysts have recently issued reports on the stock. Johnson Rice set a $190.00 price objective on shares of Johnson & Johnson and gave the stock a “hold” rating in a report on Wednesday, October 22nd. Leerink Partners raised their price target on Johnson & Johnson from $201.00 to $232.00 and gave the company a “market perform” rating in a research report on Thursday, January 22nd. Stifel Nicolaus upped their price objective on Johnson & Johnson from $205.00 to $220.00 and gave the stock a “hold” rating in a report on Thursday, January 22nd. Barclays raised their price objective on Johnson & Johnson from $197.00 to $217.00 and gave the company an “equal weight” rating in a report on Tuesday, December 30th. Finally, Sanford C. Bernstein upped their target price on Johnson & Johnson from $208.00 to $225.00 and gave the stock a “market perform” rating in a research note on Friday, January 23rd. One research analyst has rated the stock with a Strong Buy rating, seventeen have given a Buy rating and eight have assigned a Hold rating to the company. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus target price of $233.05.

Johnson & Johnson Profile

Johnson & Johnson is a multinational healthcare company headquartered in New Brunswick, New Jersey, that develops, manufactures and markets a broad range of products across pharmaceuticals, medical devices and previously consumer health. Founded in 1886 by the Johnson family, the company has grown into a global healthcare organization with operations and sales in many countries around the world.

The company’s pharmaceuticals business, organized largely under its Janssen research and development organization, focuses on prescription medicines across therapeutic areas such as immunology, infectious disease, oncology and neuroscience.